Abstract:Background: beta-Amyloid (A beta) fibrillation is critical for A beta deposition and cytotoxicity during the progression of Alzheimer's disease (AD). Consequently, anti-A beta monoclonal antibody drugs targeting A beta oligomers and aggregation are considered potential therapeutic strategies for AD treatment. Similar to the working mechanisms of anti-A beta monoclonal antibody drugs, our study identified osmundacetone (OAC), a small-molecule compound isolated from the traditional Chinese medicine Rhizoma Osmundae, as exerting anti-AD effects by targeting A beta. Purpose: This study sought to determine whether OAC influences the A beta burden in APP/PS1 mice and to identify potential regulatory mechanisms. Methods: Five-month-old APP/PS1 mice were injected intraperitoneally with OAC at a dose of 1 mg/kg for 12 weeks. The cognitive functions of the mice were assessed via the Morris water maze test and the open field test. Osmundacetone was analyzed via molecular docking, an isothermal dose-response fingerprint-cellular context thermal shift assay, a thioflavine T fluorescence assay, and an atomic force microscopy assay to analyze the effects of OAC on A beta fibrillation. Immunofluorescence, immunoblotting, and immunohistochemistry were used to assess A beta clearance, AD pathology, oxidative stress, and inflammatory responses. Results: The innovative biochemical and physical data illustrated that the ability of OAC to inhibit A beta fibrillation was accomplished by binding directly to A beta, which differed from the majority of previously reported natural polyphenols that modulate the A beta content and structure in an indirect manner. The inhibition of A beta fibrosis by OAC subsequently promoted A beta lysosomal degradation, resulting in a decreased A beta burden in APP/PS1 mice. Furthermore, OAC treatment inhibited oxidative damage by upregulating glutathione peroxidase expression and attenuated the production of inflammatory factors by downregulating nuclear factor-kB phosphorylation in APP/ PS1 mice. Conclusion: These findings demonstrate, for the first time, that OAC could reduce the brain A beta burden in APP/PS1 mice by inhibiting A beta fibrillation through direct binding to A beta and improve cognitive dysfunction by attenuating oxidative damage and neuroinflammation. These findings indicate that OAC may be a promising candidate for the treatment of AD.

Osteocalcin ameliorates cognitive dysfunctions in a mouse model of Alzheimer's Disease by reducing amyloid β burden and upregulating glycolysis in neuroglia

Osteocalcin Ameliorates Cognitive Dysfunctions in a Mouse Model of Alzheimer’s Disease by Reducing Amyloid Β Burden and Upregulating Glycolysis in Neuroglia

Thiamme2-G, a Novel O-GlcNAcase Inhibitor, Reduces Tau Hyperphosphorylation and Rescues Cognitive Impairment in Mice

OGDHL ameliorates cognitive impairment and Alzheimer's disease-like pathology via activating Wnt/β-catenin signaling in Alzheimer's disease mice

Osmundacetone ameliorates Alzheimer's-like pathologies by inhibiting β-amyloid fibrillation, oxidative damage and neuroinflammation in APP/PS1 transgenic mice

Osmundacetone Ameliorates Alzheimer's-like Pathologies by Inhibiting (3-Amyloid Fibrillation, Oxidative Damage and Neuroinflammation in APP/ PS1 Transgenic Mice

Osteoclasts Link Dysregulated Peripheral Degradation Processes and Accelerated Progression in Alzheimer's Disease

The Protective Effects of Osteocyte‐Derived Extracellular Vesicles Against Alzheimer's Disease Diminished with Aging

Osteocalcin Ameliorates Motor Dysfunction in a 6-Hydroxydopamine-induced Parkinson’s Disease Rat Model Through AKT/GSK3β Signaling

Orientin Alleviates Cognitive Deficits and Oxidative Stress in Aβ1–42-induced Mouse Model of Alzheimer's Disease

Causal Effect of Blood Osteocalcin on the Risk of Alzheimer’s Disease and the Mediating Role of Energy Metabolism

Causal effect of blood osteocalcin on the risk of Alzheimer's disease and the mediating role of energy metabolism

Long-term inhibition of ODC1 in APP/PS1 mice rescues amyloid pathology and switches astrocytes from a reactive to active state

Senolytic therapy alleviates Aβ-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer’s disease model

Morinda Officinalis Oligosaccharides Alleviate Cognitive Dysfunction Through Depressing Β-Amyloid Deposition and ER Stress in Alzheimer'S Disease

Cognitive enhancement and neuroprotective effects of OABL, a sesquiterpene lactone in 5xFAD Alzheimer's disease mice model

Gpr158 mediates osteocalcin’s regulation of cognition

Astragalus polysaccharide alleviates cognitive impairment and β-amyloid accumulation in APP/PS1 mice via Nrf2 pathway

N-Acetyl Chitooligosaccharides Attenuate Amyloid Β-Induced Damage in Animal and Cell Models of Alzheimer’s Disease

Oxyphylla A ameliorates cognitive deficits and alleviates neuropathology via the Akt-GSK3β and Nrf2-Keap1-HO-1 pathways in vitro and in vivo murine models of Alzheimer's disease

Cholecystokinin Signaling Can Rescue Cognition and Synaptic Plasticity in the APP/PS1 Mouse Model of Alzheimer's Disease.